Clinical Trial Update: Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study [Phase 2]

View source ↗

Summary

Exploratory Phase 2 study evaluating pyrotinib in combination with nab-paclitaxel for HER2-positive advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN